HCA Healthcare, Inc. $HCA Shares Sold by iA Global Asset Management Inc.

Posted by Brenda Bartman on May 17th, 2026

iA Global Asset Management Inc. trimmed its position in shares of HCA Healthcare, Inc. (NYSE:HCA – Free Report) by 5.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,821 shares of the company’s stock after selling 2,243 shares during the period. iA Global Asset Management Inc.’s holdings in HCA Healthcare were worth $19,991,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Palisade Asset Management LLC acquired a new stake in shares of HCA Healthcare in the third quarter valued at $26,000. Holos Integrated Wealth LLC purchased a new position in HCA Healthcare in the fourth quarter valued at $29,000. Ares Financial Consulting LLC purchased a new position in HCA Healthcare in the fourth quarter valued at $31,000. JPL Wealth Management LLC purchased a new position in HCA Healthcare in the third quarter valued at $33,000. Finally, Aventura Private Wealth LLC purchased a new position in HCA Healthcare in the fourth quarter valued at $34,000. 62.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Michael R. Mcalevey sold 1,694 shares of HCA Healthcare stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $533.37, for a total transaction of $903,528.78. Following the completion of the sale, the executive vice president directly owned 8,853 shares in the company, valued at approximately $4,721,924.61. This trade represents a 16.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.50% of the company’s stock.

HCA Healthcare Trading Down 2.3%

Shares of HCA opened at $422.68 on Friday. HCA Healthcare, Inc. has a twelve month low of $330.00 and a twelve month high of $556.52. The stock’s 50 day moving average is $478.74 and its two-hundred day moving average is $485.84. The firm has a market capitalization of $93.77 billion, a PE ratio of 14.54, a P/E/G ratio of 1.34 and a beta of 1.18.

HCA Healthcare (NYSE:HCA – Get Free Report) last announced its quarterly earnings data on Friday, April 24th. The company reported $7.15 earnings per share for the quarter, missing analysts’ consensus estimates of $7.19 by ($0.04). HCA Healthcare had a net margin of 8.89% and a negative return on equity of 295.93%. The business had revenue of $19.11 billion during the quarter, compared to analysts’ expectations of $19.09 billion. During the same period in the prior year, the firm posted $6.45 EPS. HCA Healthcare’s revenue for the quarter was up 4.3% compared to the same quarter last year. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. On average, sell-side analysts predict that HCA Healthcare, Inc. will post 30.07 EPS for the current year.

HCA Healthcare Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 16th will be issued a $0.78 dividend. This represents a $3.12 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Tuesday, June 16th. HCA Healthcare’s payout ratio is currently 10.73%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on HCA. Truist Financial cut their target price on HCA Healthcare from $546.00 to $535.00 and set a “buy” rating on the stock in a research report on Monday, April 27th. UBS Group lifted their target price on HCA Healthcare from $598.00 to $635.00 and gave the stock a “buy” rating in a research report on Monday, February 23rd. Weiss Ratings reiterated a “buy (b)” rating on shares of HCA Healthcare in a research report on Friday, March 27th. JPMorgan Chase & Co. upped their price target on shares of HCA Healthcare from $420.00 to $535.00 and gave the company a “neutral” rating in a research report on Friday, February 20th. Finally, Robert W. Baird reduced their price target on shares of HCA Healthcare from $450.00 to $442.00 and set a “neutral” rating for the company in a research report on Wednesday, April 15th. Sixteen research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $517.82.

View Our Latest Stock Report on HCA Healthcare

HCA Healthcare Company Profile

(Free Report)

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.